Immunovant to Present at Roivant Investor Day on September 28th

Rhea-AI Summary

On September 21, 2022, Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate update at Roivant’s Investor Day on September 28, 2022, at 11:15 AM ET. The event will include a webcast available on the company's website. Immunovant focuses on developing therapies for autoimmune diseases and is known for its investigational compound, batoclimab, a monoclonal antibody targeting FcRn. The company aims to meet significant unmet patient needs in this sector.

News Market Reaction – IMVT

+3.04%

+3.04% Session move

In the trading session that priced this news, IMVT gained 3.04%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivant’s Investor Day, taking place on September 28^th, 2022.

Roivant Investor Day presentation details:
Date:	Wednesday, September 28th, 2022
Time:	11:15 am Eastern Time
Webcast:	The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com. 

Contact:

Chau Cheng, PhD, MBA
VP Investor Relations
Immunovant, Inc.
info@immunovant.com

FAQ

What is the date of Immunovant's presentation at Roivant's Investor Day?

Immunovant's presentation is scheduled for September 28, 2022.

What time will the Immunovant presentation take place?

The presentation will occur at 11:15 AM Eastern Time.

Where can I access the webcast for the Immunovant presentation?

The webcast will be available on Immunovant's Investor Relations section of their website.

What is the focus of Immunovant's research and development?

Immunovant is focused on developing therapies for autoimmune diseases.

What is batoclimab?

Batoclimab is an investigational compound developed by Immunovant, targeting the neonatal Fc receptor (FcRn).